AndreyPopov/iStock via Getty Images Applied Therapeutics (NASDAQ:APLT) announced positive 12-month interim results from its phase 3 INSPIRE study using AT-007 for the treatment of patients with Sorbitol dehydrogenase deficiency [SORD deficiency]. The last time I spoke about this biotech, I noted that it had several value generating inflection points using AT-007 for the treatment of patients with rare diseases. I spoke about such possible inflection points in a prior Seeking Alpha article entitled "Applied ...